---
schema_version: "secwatch.filing_event.v1"
accession: "0001705843-25-000010"
form_type: "8-K"
ticker: "CBUS"
cik: "0001705843"
company_name: "Cibus, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:16:40.212618+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cibus Q2 net loss narrows to $26.6M; cash runway into Q2 2026; Rice trait commercialization on track

## Summary
- Net loss $26.6M ($0.61 per share) vs $28.5M ($1.14) YoY; R&D $12.2M, SG&A $6.6M, both down on cost cuts.
- Cash $36.5M at June 30; raised $27.5M gross from June offering; expects funding into Q2 2026.
- Streamlining targets annual cash usage ~$30M by 2026; focused on Rice herbicide tolerance and partner-funded programs.
- Rice HT1/HT3 traits on track for Latin America launch 2027, US 2028; signed collaboration with Colombia's Semillano; delivered HT3 lines to US customer.
- Sustainable ingredients program on track for nominal 2025 revenues; regulatory wins: Ecuador cleared HT1/HT3 as non-GMO, USDA deregulated HT2 canola.

## SEC filing metadata
- accession: 0001705843-25-000010
- form_type: 8-K
- ticker: CBUS
- cik: 0001705843
- company_name: Cibus, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1705843/000170584325000010/0001705843-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1705843/000170584325000010/cbus-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001705843-25-000010
- JSON: https://secwatch.observer/filing/0001705843-25-000010.json
- Plain text: https://secwatch.observer/filing/0001705843-25-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.